Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Sep;33(3):519-24.

An open randomized clinical trial of Artecom vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand

P Wilairatana  1 , S Krudsood, K Chalermrut, C Pengruksa, S Srivilairit, U Silachamroon, S Treeprasertsuk, S Looareesuwan
Affiliations
  • PMID: 12693586
Clinical Trial

An open randomized clinical trial of Artecom vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand

P Wilairatana et al. Southeast Asian J Trop Med Public Health. 2002 Sep.

Abstract

The efficacy and safety of Artecom were assessed in an open randomized trial in adults presenting with acute, uncomplicated Plasmodium falciparum malaria in Thailand. Three hundred and fifty-two patients were randomly enroled at the ratio of 2:1 into group A:B and received Artecom (group A) and the standard combination of artesunate and mefloquine (group B) respectively. All patients had rapid initial clinical and parasitological responses. There were no significant differences in fever clearance time and parasite clearance time between the two groups. The 28-day cure rates were high as 97% in both groups. Artecom was effective and well-tolerated as artesunate-mefloquine, the current treatment in this area of multidrug-resistant P. falciparum malaria.

PubMed Disclaimer

Publication types